

Anna M Czarnecka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3404548/publications.pdf>

Version: 2024-02-01

182
papers

3,629
citations

172457

29
h-index

197818

49
g-index

191
all docs

191
docs citations

191
times ranked

5659
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2168-2174.	2.2	5
2	Treatment of Locally Advanced Merkel Cell Carcinoma—A Multi-Center Study. <i>Cancers</i> , 2022, 14, 422.	3.7	3
3	Efficacy of immunotherapy beyond RECIST progression in advanced melanoma: a real-world evidence. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1949-1958.	4.2	7
4	Treatment of Malignant Adnexal Tumors of the Skin: A 12-Year Perspective. <i>Cancers</i> , 2022, 14, 998.	3.7	4
5	Efficacy of Neoadjuvant Targeted Therapy for Borderline Resectable III B-D or IV Stage BRAF V600 Mutation-Positive Melanoma. <i>Cancers</i> , 2022, 14, 110.	3.7	5
6	New Perspectives for Eye-Sparing Treatment Strategies in Primary Uveal Melanoma. <i>Cancers</i> , 2022, 14, 134.	3.7	8
7	Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence. <i>Journal of Clinical Medicine</i> , 2022, 11, 2239.	2.4	6
8	Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients. <i>Cancers</i> , 2022, 14, 2123.	3.7	2
9	Imaging of Uveal Melanoma—Current Standard and Methods in Development. <i>Cancers</i> , 2022, 14, 3147.	3.7	19
10	Endoglin Expression and Microvessel Density as Prognostic Factors in Pediatric Rhabdomyosarcoma. <i>Journal of Clinical Medicine</i> , 2021, 10, 512.	2.4	6
11	Rozpoznanie i leczenie limfangioleiomiomatozy (LAM) z grupy PEComa. <i>Oncology in Clinical Practice</i> , 2021, 17, 28-41.	0.1	1
12	Radiotherapy in the Management of Pediatric and Adult Osteosarcomas: A Multi-Institutional Cohort Analysis. <i>Cells</i> , 2021, 10, 366.	4.1	7
13	The Management of Radiation-Induced Sarcomas: A Cohort Analysis from a Sarcoma Tertiary Center. <i>Journal of Clinical Medicine</i> , 2021, 10, 694.	2.4	10
14	First-line treatment of advanced/metastatic melanoma with anti-PD-1 antibodies: multicenter experience in Poland. <i>Immunotherapy</i> , 2021, 13, 297-307.	2.0	6
15	Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 723-742.	2.3	13
16	Biological Heterogeneity of Chondrosarcoma: From (Epi) Genetics through Stemness and Deregulated Signaling to Immunophenotype. <i>Cancers</i> , 2021, 13, 1317.	3.7	6
17	Current Diagnosis and Treatment Options for Cutaneous Adnexal Neoplasms with Follicular Differentiation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4759.	4.1	9
18	Current Diagnosis and Treatment Options for Cutaneous Adnexal Neoplasms with Apocrine and Eccrine Differentiation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5077.	4.1	23

#	ARTICLE	IF	CITATIONS
19	Chondrosarcoma-from Molecular Pathology to Novel Therapies. <i>Cancers</i> , 2021, 13, 2390.	3.7	31
20	Feasibility and Long-Term Efficacy of PEComa Treatmentâ€™20 Years of Experience. <i>Journal of Clinical Medicine</i> , 2021, 10, 2200.	2.4	15
21	Hyperpolarized 13C tracers: Technical advancements and perspectives for clinical applications. <i>Biocybernetics and Biomedical Engineering</i> , 2021, 41, 1466-1485.	5.9	2
22	Treatment beyond progression with immune checkpoint inhibitors in advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21541-e21541.	1.6	1
23	Systemic treatment of patients with inoperable and metastatic Merkel cell carcinoma: A multicenter study.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21521-e21521.	1.6	0
24	Comparison of the efficacy and toxicity of anti-PD-1 monoclonal antibodies (nivolumab versus) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 54. <i>Journal of Clinical Oncology</i> , 2021, 39, e21514-e21514.	1.6	2
25	Merkel Cell Carcinoma from Molecular Pathology to Novel Therapies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6305.	4.1	20
26	Combined Preoperative Hypofractionated Radiotherapy With Doxorubicin-Ifosfamide Chemotherapy in Marginally Resectable Soft Tissue Sarcomas: Results of a Phase 2 Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1053-1063.	0.8	14
27	TP53 in Biology and Treatment of Osteosarcoma. <i>Cancers</i> , 2021, 13, 4284.	3.7	26
28	Efficacy of Sirolimus Treatment in PEComaâ€™10 Years of Practice Perspective. <i>Journal of Clinical Medicine</i> , 2021, 10, 3705.	2.4	12
29	What is the best front-line approach in patients with desmoid fibromatosis? â€™ A retrospective analysis from a reference center. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2602-2608.	1.0	7
30	Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patients. <i>Melanoma Research</i> , 2021, 31, 49-57.	1.2	4
31	Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. <i>Cancer</i> , 2020, 126, 98-104.	4.1	25
32	The Long-Term Outcomes of Intensive Combined Therapy of Adult Patients with Localised Synovial Sarcoma. <i>Journal of Clinical Medicine</i> , 2020, 9, 3129.	2.4	0
33	Malignant peripheral nerve sheath tumors â€™ Outcomes and prognostic factors based on the reference center experience. <i>Surgical Oncology</i> , 2020, 35, 276-284.	1.6	4
34	Epithelioid Sarcomaâ€™From Genetics to Clinical Practice. <i>Cancers</i> , 2020, 12, 2112.	3.7	32
35	Neoadjuvant Treatment Options in Soft Tissue Sarcomas. <i>Cancers</i> , 2020, 12, 2061.	3.7	20
36	Molecular Biology of Osteosarcoma. <i>Cancers</i> , 2020, 12, 2130.	3.7	198

#	ARTICLE	IF	CITATIONS
37	Multimodal Treatment of Advanced Mucosal Melanoma in the Era of Modern Immunotherapy. <i>Cancers</i> , 2020, 12, 3131.	3.7	13
38	Clinicopathological Features and Prognostic Factors of Primary Acral Melanomas in Caucasians. <i>Journal of Clinical Medicine</i> , 2020, 9, 2996.	2.4	10
39	BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma. <i>Melanoma Research</i> , 2020, 30, 465-471.	1.2	14
40	Efficacy of ipilimumab after anti-PD-1 therapy in sequential treatment of metastatic melanoma patients - Real world evidence. <i>Advances in Medical Sciences</i> , 2020, 65, 316-323.	2.1	12
41	Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. <i>Cancer</i> , 2020, 126, 2637-2647.	4.1	86
42	TP53-Deficient Angiosarcoma Expression Profiling in Rat Model. <i>Cancers</i> , 2020, 12, 1525.	3.7	3
43	Targeted Therapy in Melanoma and Mechanisms of Resistance. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4576.	4.1	107
44	Choosing The Right Animal Model for Renal Cancer Research. <i>Translational Oncology</i> , 2020, 13, 100745.	3.7	35
45	Renal carcinoma CD105 ⁺ /CD44 ⁺ cells display stem-like properties in vitro and form aggressive tumors in vivo. <i>Scientific Reports</i> , 2020, 10, 5379.	3.3	17
46	An update on the safety of nivolumab for the treatment of advanced melanoma. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 409-421.	2.4	5
47	Mutation profile of primary subungual melanomas in Caucasians. <i>Oncotarget</i> , 2020, 11, 2404-2413.	1.8	13
48	Systemic Treatment for Advanced and Metastatic Malignant Peripheral Nerve Sheath Tumors – A Sarcoma Reference Center Experience. <i>Journal of Clinical Medicine</i> , 2020, 9, 3157.	2.4	9
49	Diagnosis and treatment of malignant PEComa tumours. <i>Oncology in Clinical Practice</i> , 2020, 16, 22-33.	0.1	23
50	Summary of immunotherapy efficacy ordered in accordance with drug reimbursement program in melanoma patients. <i>Oncology in Clinical Practice</i> , 2020, 16, 56-68.	0.1	1
51	Rozpoznanie i leczenie nowotworów typu angiomyolipoma (AML). <i>Oncology in Clinical Practice</i> , 2020, 16, 116-132.	0.1	4
52	Czerniak skóry. <i>Oncology in Clinical Practice</i> , 2020, 16, 163-182.	0.1	8
53	Correlation of immunity-related adverse events with survival and response to anti-PD-1 treatment in patients with metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15164-e15164.	1.6	0
54	Prognostic and predictive factors for the outcomes of clear cell sarcoma (CCS) multidisciplinary treatment: The role of lymph node involvement.. <i>Journal of Clinical Oncology</i> , 2020, 38, e23554-e23554.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Radioterapia chorych na czerniaka. <i>Oncology in Clinical Practice</i> , 2020, 15, 310-319.	0.1	2
56	Porównanie po średnie wyniki leczenia chorych na zaawansowane/przerzutowe czerniaki za pomocą... niwolumabu lub pembrolizumabu – analiza wielośrodkowa. <i>Oncology in Clinical Practice</i> , 2020, 16, 295-300.	0.1	1
57	Prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in patients with advanced gastrointestinal stromal tumors treated with sunitinib after imatinib failure. <i>Oncology Letters</i> , 2019, 18, 3373-3380.	1.8	4
58	The analysis of current treatment outcomes in melanoma patients with brain metastases. <i>Annals of Oncology</i> , 2019, 30, v555-v556.	1.2	0
59	Drug resistance in papillary RCC: from putative mechanisms to clinical practicalities. <i>Nature Reviews Urology</i> , 2019, 16, 655-673.	3.8	24
60	OC-0069 5x5 Gy with chemotherapy in borderline resectable soft tissue sarcomas: early results of a trial. <i>Radiotherapy and Oncology</i> , 2019, 133, S31-S32.	0.6	12
61	Metastatic renal cell carcinoma cells growing in 3D on poly-D-lysine or laminin present a stem-like phenotype and drug resistance. <i>Oncology Reports</i> , 2019, 42, 1878-1892.	2.6	12
62	Metastatic Tumor Burden and Loci as Predictors of First Line Sunitinib Treatment Efficacy in Patients with Renal Cell Carcinoma. <i>Scientific Reports</i> , 2019, 9, 7754.	3.3	10
63	Insulin and insulin-like growth factors act as renal cell cancer intratumoral regulators. <i>Journal of Cell Communication and Signaling</i> , 2019, 13, 381-394.	3.4	29
64	Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice. <i>Targeted Oncology</i> , 2019, 14, 729-742.	3.6	18
65	Persistent Overexposure to N-Methyl-d-Aspartate (NMDA) Calcium-Dependently Downregulates Glutamine Synthetase, Aquaporin 4, and Kir4.1 Channel in Mouse Cortical Astrocytes. <i>Neurotoxicity Research</i> , 2019, 35, 271-280.	2.7	25
66	Development of extracellular matrix supported 3D culture of renal cancer cells and renal cancer stem cells. <i>Cytotechnology</i> , 2019, 71, 149-163.	1.6	17
67	Mechanisms of melanoma resistance to treatment with BRAF and MEK inhibitors. <i>Nowotwory</i> , 2019, 69, 133-141.	0.3	2
68	Molecular biology of sarcoma. <i>Oncology in Clinical Practice</i> , 2019, 14, 307-330.	0.1	8
69	Clear cell sarcoma. <i>Oncology in Clinical Practice</i> , 2019, 14, 354-363.	0.1	2
70	Malignant peripheral nerve sheath tumour (MPNST). <i>Oncology in Clinical Practice</i> , 2019, 14, 364-376.	0.1	4
71	Mucosal melanoma – clinical presentation and treatment based on a case series. <i>Oncology in Clinical Practice</i> , 2019, 15, 223-230.	0.1	2
72	Leczenie pembrolizumabem w pierwszej linii w uogólnionym czerniaku z wykrytą... mutacją... w kodonie V600 genu BRAF oraz z izolowan... progresją... choroby w m...zgu. <i>Oncology in Clinical Practice</i> , 2019, 14, 28-33.	0.1	0

#	ARTICLE	IF	CITATIONS
73	Clinicopathological prognostic and predictive factors of malignant peripheral nerve sheath tumors (MPNST) survival and treatment efficacy.. Journal of Clinical Oncology, 2019, 37, e22537-e22537.	1.6	0
74	Culture in embryonic kidney serum and xeno-free media as renal cell carcinoma and renal cell carcinoma cancer stem cells research model. Cytotechnology, 2018, 70, 761-782.	1.6	4
75	Effect of Everolimus on Heterogenous Renal Cancer Cells Populations Including Renal Cancer Stem Cells. Stem Cell Reviews and Reports, 2018, 14, 385-397.	5.6	3
76	Treatment outcomes in older patients with advanced gastrointestinal stromal tumor (GIST). Journal of Geriatric Oncology, 2018, 9, 520-525.	1.0	10
77	Preoperative hypofractionated radiotherapy (RT) combined with chemotherapy in primary marginally resectable high grade soft tissue sarcomas (STS) of extremities or trunk wall: Interim analysis of prospective phase II clinical trial. Annals of Oncology, 2018, 29, viii585-viii586.	1.2	2
78	The analysis of treatment sequencing and clinical outcomes in BRAF-positive and BRAF-negative unresectable/metastatic melanoma patients treated with systemic therapies in routine practice. Annals of Oncology, 2018, 29, viii451.	1.2	0
79	Cerebrovascular reactivity and cerebral perfusion of rats with acute liver failure: role of L-glutamine and asymmetric dimethylarginine in L-arginine-induced response. Journal of Neurochemistry, 2018, 147, 692-704.	3.9	4
80	High baseline neutrophil-to-lymphocyte ratio predicts worse outcome in patients with metastatic BRAF-positive melanoma treated with BRAF and MEK inhibitors. Melanoma Research, 2018, 28, 435-441.	1.2	9
81	Three-Dimensional Cell Culture Model Utilization in Renal Carcinoma Cancer Stem Cell Research. Methods in Molecular Biology, 2018, 1817, 47-66.	0.9	11
82	Surface markers of cancer stem-like cells of ovarian cancer and their clinical relevance. Wspolczesna Onkologia, 2018, 2018, 48-55.	1.4	30
83	Biomarkers defining probability of receiving second-line targeted therapy in metastatic renal cell carcinoma. Medical Oncology, 2018, 35, 91.	2.5	2
84	Involvement of the CB2 cannabinoid receptor in cell growth inhibition and G0/G1 cell cycle arrest via the cannabinoid agonist WIN 55,212-2 in renal cell carcinoma. BMC Cancer, 2018, 18, 583.	2.6	34
85	Doxorubicin plus dacarbazine (DoDa), doxorubicin plus ifosfamide (DI) or doxorubicin alone (Do) as first line treatment for advanced leiomyosarcoma (LMS): A retrospective study from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG).. Journal of Clinical Oncology, 2018, 36, 11574-11574.	1.6	6
86	Association of breathing patterns and quality of life in patients with nasal obstruction. Otolaryngologia Polska, 2018, 72, 11-15.	0.6	3
87	Intermittent sunitinib is an effective renal carcinoma treatment. Nature Reviews Urology, 2017, 14, 264-266.	3.8	1
88	Colony, hanging drop, and methylcellulose three dimensional hypoxic growth optimization of renal cell carcinoma cell lines. Cytotechnology, 2017, 69, 565-578.	1.6	16
89	Immuno-oncology for renal cell carcinoma treatment: future perspectives for combinations and sequences with molecularly targeted agents. Expert Opinion on Biological Therapy, 2017, 17, 151-162.	3.1	4
90	Depressive-like neurochemical and behavioral markers of Parkinson's disease after 6-OHDA administered unilaterally to the rat medial forebrain bundle. Pharmacological Reports, 2017, 69, 985-994.	3.3	33

#	ARTICLE	IF	CITATIONS
91	Renin angiotensin system deregulation as renal cancer risk factor (Review). <i>Oncology Letters</i> , 2017, 14, 5059-5068.	1.8	35
92	Functional significance of CD105-positive cells in papillary renal cell carcinoma. <i>BMC Cancer</i> , 2017, 17, 21.	2.6	16
93	Cardiac safety of systemic therapy in breast cancer patients with high risk of atherosclerosis complications. <i>Future Oncology</i> , 2017, 13, 593-602.	2.4	4
94	The significance of rotational behavior and sensitivity of striatal dopamine receptors in hemiparkinsonian rats: A comparative study of lactacystin and 6-OHDA. <i>Neuroscience</i> , 2017, 340, 308-318.	2.3	13
95	Three-dimensional cell culture model utilization in cancer stem cell research. <i>Biological Reviews</i> , 2017, 92, 1505-1520.	10.4	95
96	Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma. <i>Future Oncology</i> , 2017, 13, 31-49.	2.4	19
97	Intracerebral Administration of S-Adenosylhomocysteine or S-Adenosylmethionine Attenuates the Increases in the Cortical Extracellular Levels of Dimethylarginines Without Affecting cGMP Level in Rats with Acute Liver Failure. <i>Neurotoxicity Research</i> , 2017, 31, 99-108.	2.7	10
98	Contribution of the nitric oxide donor molsidomine and the antiparkinsonian drug l-DOPA to the modulation of the blood pressure in unilaterally 6-OHDA-lesioned rats. <i>Pharmacological Reports</i> , 2017, 69, 29-35.	3.3	2
99	Asymmetric Dimethylarginine and Hepatic Encephalopathy: Cause, Effect or Association?. <i>Neurochemical Research</i> , 2017, 42, 750-761.	3.3	14
100	Hypoxic 3D in vitro culture models reveal distinct resistance processes to TKIs in renal cancer cells. <i>Cell and Bioscience</i> , 2017, 7, 71.	4.8	22
101	Effects of cell-cell crosstalk on gene expression patterns in a cell model of renal cell carcinoma lung metastasis. <i>International Journal of Oncology</i> , 2017, 52, 768-786.	3.3	5
102	Pazopanib in Patients with Clear-Cell Renal Cell Carcinoma: Seeking the Right Patient. <i>Frontiers in Pharmacology</i> , 2017, 8, 329.	3.5	5
103	The Therapeutic Aspects of the Endocannabinoid System (ECS) for Cancer and their Development: From Nature to Laboratory. <i>Current Pharmaceutical Design</i> , 2016, 22, 1756-1766.	1.9	43
104	Thyroid Hormones as Renal Cell Cancer Regulators. <i>Journal of Signal Transduction</i> , 2016, 2016, 1-8.	2.0	8
105	Insulin-like growth factor-1 signaling in renal cell carcinoma. <i>BMC Cancer</i> , 2016, 16, 453.	2.6	49
106	Management of pediatric head and neck rhabdomyosarcoma: A case-series of 36 patients. <i>Oncology Letters</i> , 2016, 12, 3555-3562.	1.8	22
107	Mechanisms through which diabetes mellitus influences renal cell carcinoma development and treatment: A review of the literature. <i>International Journal of Molecular Medicine</i> , 2016, 38, 1887-1894.	4.0	32
108	Chemotherapy of pancreatic solid pseudopapillary carcinoma – A case report and a literature review. <i>Cancer Treatment Communications</i> , 2016, 7, 47-51.	0.4	3

#	ARTICLE	IF	CITATIONS
109	Tyrosine kinase inhibitors target cancer stem cells in renal cell cancer. <i>Oncology Reports</i> , 2016, 35, 1433-1442.	2.6	12
110	Gene set enrichment analysis and ingenuity pathway analysis of metastatic clear cell renal cell carcinoma cell line. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 311, F424-F436.	2.7	25
111	Hormone signaling pathways as treatment targets in renal cell cancer (Review). <i>International Journal of Oncology</i> , 2016, 48, 2221-2235.	3.3	42
112	Triiodothyronine regulates cell growth and survival in renal cell cancer. <i>International Journal of Oncology</i> , 2016, 49, 1666-1678.	3.3	12
113	Choosing the right cell line for renal cell cancer research. <i>Molecular Cancer</i> , 2016, 15, 83.	19.2	205
114	Prolonged complete response following gemcitabine-erlotinib combined therapy in advanced pancreatic cancer. <i>Oncology Letters</i> , 2016, 11, 1101-1104.	1.8	8
115	Comparative Gene Expression Profiling of Primary and Metastatic Renal Cell Carcinoma Stem Cell-Like Cancer Cells. <i>PLoS ONE</i> , 2016, 11, e0165718.	2.5	29
116	Gene expression profiling of primary and metastatic renal cell carcinoma tumor initiating cells.. <i>Journal of Clinical Oncology</i> , 2016, 34, e16091-e16091.	1.6	0
117	The role of the cell-cell interactions in cancer progression. <i>Journal of Cellular and Molecular Medicine</i> , 2015, 19, 283-296.	3.6	89
118	Impaired glucose metabolism treatment and carcinogenesis. <i>Oncology Letters</i> , 2015, 10, 589-594.	1.8	6
119	The Role of Diabetes in Molecular Pathogenesis of Cancer. <i>Current Signal Transduction Therapy</i> , 2015, 10, 10-16.	0.5	1
120	Nasopharyngeal chordoma in a patient with a severe form of sleep-disordered breathing: A case report. <i>Oncology Letters</i> , 2015, 10, 1805-1809.	1.8	2
121	Review Rhabdomyosarcoma of the head and neck in children. <i>Wspolczesna Onkologia</i> , 2015, 2, 98-107.	1.4	29
122	Review Biology of renal tumour cancer stem cells applied in medicine. <i>Wspolczesna Onkologia</i> , 2015, 1A, 44-51.	1.4	12
123	Current approaches in identification and isolation of human renal cell carcinoma cancer stem cells. <i>Stem Cell Research and Therapy</i> , 2015, 6, 178.	5.5	57
124	Molecular basis of carcinogenesis in diabetic patients (Review). <i>International Journal of Oncology</i> , 2015, 46, 1435-1443.	3.3	9
125	Decreased behavioral response to intranigally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: Comparison to the classical neurotoxin 6-OHDA. <i>Behavioural Brain Research</i> , 2015, 283, 203-214.	2.2	9
126	Future perspectives for mTOR inhibitors in renal cell cancer treatment. <i>Future Oncology</i> , 2015, 11, 801-817.	2.4	13

#	ARTICLE	IF	CITATIONS
127	Long-term parental satisfaction with adenotonsillectomy: a population study. <i>Sleep and Breathing</i> , 2015, 19, 1425-1429.	1.7	1
128	The preferential nNOS inhibitor 7-nitroindazole and the non-selective one NG-nitro-L-arginine methyl ester administered alone or jointly with L-DOPA differentially affect motor behavior and monoamine metabolism in sham-operated and 6-OHDA-lesioned rats. <i>Brain Research</i> , 2015, 1625, 218-237.	2.2	2
129	Development of chronic myeloid leukaemia in patients treated with anti-VEGF therapies for clear cell renal cell cancer. <i>Future Oncology</i> , 2015, 11, 17-26.	2.4	16
130	Interleukin-6 as an emerging regulator of renal cell cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 476-485.	1.6	45
131	Insulin and IGFs in renal cancer risk and progression. <i>Endocrine-Related Cancer</i> , 2015, 22, R253-R264.	3.1	54
132	The Role of Hypoxia and Cancer Stem Cells in Renal Cell Carcinoma Pathogenesis. <i>Stem Cell Reviews and Reports</i> , 2015, 11, 919-943.	5.6	72
133	Obstructive sleep apnea and cancer: effects of intermittent hypoxia?. <i>Future Oncology</i> , 2015, 11, 3285-3298.	2.4	15
134	Feasibility, efficacy and safety of tyrosine kinase inhibitor treatment in hemodialyzed patients with renal cell cancer: 10 years of experience. <i>Future Oncology</i> , 2015, 11, 2267-2282.	2.4	25
135	Snoring but not BMI influences aggressive behavior and concentration problems in children. <i>Otolaryngologia Polska</i> , 2015, 69, 21-25.	0.6	4
136	Molecular events regulating clear cell renal cell cancer resistance to tyrosine kinase inhibitors.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15600-e15600.	1.6	0
137	Mammalian Target of Rapamycin Inhibitors Resistance Mechanisms in Clear Cell Renal Cell Carcinoma. <i>Current Signal Transduction Therapy</i> , 2014, 8, 210-218.	0.5	20
138	Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC). <i>Current Signal Transduction Therapy</i> , 2014, 8, 219-228.	0.5	67
139	Metastasis-Initiating Cells in Renal Cancer. <i>Current Signal Transduction Therapy</i> , 2014, 8, 240-246.	0.5	17
140	Clinical and molecular prognostic and predictive biomarkers in clear cell renal cell cancer. <i>Future Oncology</i> , 2014, 10, 2493-2508.	2.4	10
141	The role of prostaglandin E2 in renal cell cancer development: future implications for prognosis and therapy. <i>Future Oncology</i> , 2014, 10, 2177-2187.	2.4	18
142	The use of sunitinib in renal cell carcinoma: where are we now?. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 983-999.	2.4	7
143	Tracheal adenoid cystic carcinoma mimicking a thyroid tumor: A case report. <i>Oncology Letters</i> , 2014, 8, 1312-1316.	1.8	11
144	Frontiers in clinical and molecular diagnostics and staging of metastatic clear cell renal cell carcinoma. <i>Future Oncology</i> , 2014, 10, 1095-1111.	2.4	32

#	ARTICLE	IF	CITATIONS
145	Genomic Analysis as the First Step toward Personalized Treatment in Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2014, 4, 194.	2.8	19
146	Renal cell carcinoma with intramyocardial metastases. <i>BMC Urology</i> , 2014, 14, 73.	1.4	10
147	Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: From the patient's bed to molecular mechanisms. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1845, 31-41.	7.4	73
148	Chronic L-DOPA treatment attenuates behavioral and biochemical deficits induced by unilateral lactacystin administration into the rat substantia nigra. <i>Behavioural Brain Research</i> , 2014, 261, 79-88.	2.2	19
149	Vitamin D receptor gene polymorphisms in breast and renal cancer: Current state and future approaches. <i>International Journal of Oncology</i> , 2014, 44, 349-363.	3.3	35
150	Renal Cell Carcinoma Cancer Stem Cells as Therapeutic Targets. <i>Current Signal Transduction Therapy</i> , 2014, 8, 203-209.	0.5	6
151	Clear Cell Renal Cell Cancer Tumor-Propagating Cells: Molecular Characteristics. <i>Current Signal Transduction Therapy</i> , 2014, 8, 229-239.	0.5	1
152	The regulation of clear cell renal cancer cells proliferation and tyrosine kinase inhibitors responsiveness by tumor micro-environmental factors.. <i>Journal of Clinical Oncology</i> , 2014, 32, 488-488.	1.6	1
153	Immunotherapy Resistance Mechanisms in Renal Cell Cancer. <i>Current Signal Transduction Therapy</i> , 2014, 8, 247-255.	0.5	0
154	Treatment obstacles for metastatic clear cell renal cell carcinoma of Fuhrman grade IV and with sarcomatoid histologies.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15604-e15604.	1.6	0
155	Molecular factors regulating clear cell renal cancer cells' fate: Implications for tyrosine kinase inhibitors responsiveness and toxicities.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15577-e15577.	1.6	0
156	Okręglony stą, 2013: zalecenia terapeutyczne w leczeniu systemowym rozlanego raka nerkowokomrkowego. <i>Nowotwory</i> , 2014, 64, 443-453.	0.3	0
157	Serum EPO and VEGF levels in patients with sleep-disordered breathing and acute myocardial infarction. <i>Sleep and Breathing</i> , 2013, 17, 1063-1069.	1.7	7
158	Hsp60 and human aging: Les liaisons dangereuses. <i>Frontiers in Bioscience - Landmark</i> , 2013, 18, 626.	3.0	26
159	Ovarian cancer as a genetic disease. <i>Frontiers in Bioscience - Landmark</i> , 2013, 18, 543.	3.0	16
160	Alterations in the expression of nNOS in the substantia nigra and subthalamic nucleus of 6-OHDA-lesioned rats: The effects of chronic treatment with L-DOPA and the nitric oxide donor, molsidomine. <i>Brain Research</i> , 2013, 1541, 92-105.	2.2	19
161	Hsp10 anatomic distribution functions and involvement in human disease. <i>Frontiers in Bioscience - Elite</i> , 2013, E5, 768-778.	1.8	25
162	Vulvar cancer as a target for molecular medicine. <i>Frontiers in Bioscience - Scholar</i> , 2011, S3, 136-144.	2.1	4

#	ARTICLE	IF	CITATIONS
163	Laryngeal embryonal rhabdomyosarcoma in an adult - A case presentation in the eyes of geneticists and clinicians. <i>BMC Cancer</i> , 2011, 11, 166.	2.6	13
164	^{99m} Tc octreotide scintigraphy and somatostatin receptor subtype expression in juvenile nasopharyngeal angiofibromas. <i>Head and Neck</i> , 2011, 33, 1739-1746.	2.0	13
165	The Role of the Mitochondrial Genome in Ageing and Carcinogenesis. <i>Journal of Aging Research</i> , 2011, 2011, 1-10.	0.9	30
166	Aggressive osteoblastoma of the sphenoid bone. <i>Oncology Letters</i> , 2010, 1, 367-371.	1.8	20
167	Mitochondrial genotype and breast cancer predisposition. <i>Oncology Reports</i> , 2010, 24, 1521-34.	2.6	26
168	Mitochondrial NADH-dehydrogenase subunit 3 (ND3) polymorphism (A10398G) and sporadic breast cancer in Poland. <i>Breast Cancer Research and Treatment</i> , 2010, 121, 511-518.	2.5	70
169	Molecular oncology focus - Is carcinogenesis a 'mitochondriopathy'? <i>Journal of Biomedical Science</i> , 2010, 17, 31.	7.0	21
170	Mitochondrial genotype in vulvar carcinoma - cuckoo in the nest. <i>Journal of Biomedical Science</i> , 2010, 17, 73.	7.0	13
171	Mitochondrial DNA mutations in cancer - from bench to bedside. <i>Frontiers in Bioscience - Landmark</i> , 2010, 15, 437.	3.0	24
172	Mitochondrial NADH-dehydrogenase polymorphisms as sporadic breast cancer risk factor. <i>Oncology Reports</i> , 2010, 23, 531-5.	2.6	17
173	Common mitochondrial polymorphisms as risk factor for endometrial cancer. <i>International Archive of Medicine</i> , 2009, 2, 33.	1.2	23
174	Breast cancer as a mitochondrial disorder (Review). <i>Oncology Reports</i> , 2009, 21, 845-51.	2.6	17
175	Mitochondrial DNA Mutations in Tumors. , 2009, , 119-130.		4
176	CD1a downregulation in primary invasive ductal breast carcinoma may predict regional lymph node invasion and patient outcome. <i>Histopathology</i> , 2008, 52, 203-212.	2.9	31
177	Upon oxidative stress, the antiapoptotic Hsp60/procaspase-3 complex persists in mucoepidermoid carcinoma cells. <i>European Journal of Histochemistry</i> , 2008, 52, 221.	1.5	54
178	Hsp60 and Hsp10 as antitumour molecular agents. <i>Cancer Biology and Therapy</i> , 2007, 6, 487-489.	3.4	36
179	Mitochondrial DNA mutations in human neoplasia. <i>Journal of Applied Genetics</i> , 2006, 47, 67-78.	1.9	75
180	Mitochondrial chaperones in cancer: From molecular biology to clinical diagnostics. <i>Cancer Biology and Therapy</i> , 2006, 5, 714-720.	3.4	138

#	ARTICLE	IF	CITATIONS
181	Heat shock protein 10 and signal transduction: a "capsula eburnea" of carcinogenesis?. Cell Stress and Chaperones, 2006, 11, 287.	2.9	50
182	Balance between Transcription and RNA Degradation Is Vital for Saccharomyces cerevisiae Mitochondria: Reduced Transcription Rescues the Phenotype of Deficient RNA Degradation. Molecular Biology of the Cell, 2006, 17, 1184-1193.	2.1	36